HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MGAT5
alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase
Chromosome 2 · 2q21.2-q21.3
NCBI Gene: 4249Ensembl: ENSG00000152127.10HGNC: HGNC:7049UniProt: Q09328
98PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein phosphatase inhibitor activityalpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase activitymanganese ion bindingprotein N-linked glycosylationAbnormality of the skeletal systemsystemic lupus erythematosusCOVID-19schizophrenia
✦AI Summary

MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase) catalyzes the addition of β1,6-linked N-acetylglucosamine to complex N-glycans, a post-translational modification with critical roles in immunity and cancer. Primary function: MGAT5 adds branched N-glycan structures to proteins, regulating protein-protein interactions and cell signaling 1. Mechanism: MGAT5-mediated β1,6-GlcNAc branching stabilizes growth factor receptors, reduces intercellular adhesion, and promotes cell migration 1. In immune cells, MGAT5 branching promotes CD8+ T-cell exhaustion through increased PD1 and Tim3 expression 2. Disease relevance: MGAT5 expression is elevated in multiple cancers, including lung adenocarcinoma and melanoma, supporting tumor growth and metastasis 34. MGAT5 expression on tumor cells shields them from CAR T cell killing by disrupting immunological synapse formation 5. Genetic variants in MGAT5 associate with severe ulcerative colitis through altered T-cell glycosylation 6. Clinical significance: MGAT5 deletion in CD8+ T cells and CAR T cells enhances anti-tumor immunity in solid tumors and glioblastoma 27. MGAT5 knockout in immunotherapy-resistant pancreatic cancer increases sensitivity to immune checkpoint blockade 8. MGAT5 represents a potential therapeutic target and prognostic biomarker in cancer and autoimmune disease.

Sources cited
1
MGAT5 deletion in CD8+ T cells reduces exhaustion markers (PD1, Tim3) and enhances tumor killing; MGAT5 knockout improves CAR T cell efficacy in solid tumors
PMID: 40828448
2
MGAT5-mediated N-glycans on tumor cells protect from CAR T cell killing by interfering with immunological synapse formation and reducing cytotoxicity
PMID: 35044789
3
MGAT5 gene editing in CD8+ T cells enhances survival in glioblastoma mouse models and improves effector functions
PMID: 31548728
4
MGAT5 catalyzes β1,6-GlcNAc branching; increased branching stabilizes growth factor receptors, destabilizes adhesion, and promotes metastasis
PMID: 36689079
5
MGAT5 is required for in vivo tumor growth; MGAT5 loss increases sensitivity to TNF superfamily-mediated cell death and enhances response to immune checkpoint blockade
PMID: 38912584
6
MGAT5 is highly expressed in CD133+ lung adenocarcinoma cells; MGAT5 knockdown inhibits cancer growth in vitro and in vivo
PMID: 21631992
7
MGAT5 genetic variants are functionally associated with altered T-cell glycosylation and UC severity, correlating with need for biologics
PMID: 32352685
8
MGAT5 overexpression alters glycosylation and proteome of extracellular vesicles in melanoma, affecting proteins associated with melanoma progression
PMID: 40199132
Disease Associationsⓘ20
Abnormality of the skeletal systemOpen Targets
0.46Moderate
systemic lupus erythematosusOpen Targets
0.44Moderate
COVID-19Open Targets
0.37Weak
schizophreniaOpen Targets
0.35Weak
skin diseaseOpen Targets
0.33Weak
biliary tract diseaseOpen Targets
0.32Weak
HypercholesterolemiaOpen Targets
0.32Weak
scleritisOpen Targets
0.32Weak
chronic lymphocytic leukemiaOpen Targets
0.32Weak
Crohn's diseaseOpen Targets
0.32Weak
substance abuseOpen Targets
0.20Weak
attention deficit hyperactivity disorderOpen Targets
0.19Weak
obesityOpen Targets
0.19Weak
cervical carcinomaOpen Targets
0.19Weak
post term pregnancyOpen Targets
0.19Weak
central nervous system infectionOpen Targets
0.19Weak
abscessOpen Targets
0.18Weak
acute tonsillitisOpen Targets
0.18Weak
HydrocephalusOpen Targets
0.18Weak
Peyronie diseaseOpen Targets
0.17Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
MGAT3Protein interaction99%MGAT5BProtein interaction99%MGAT4DProtein interaction91%LGALS3Protein interaction89%MGAT4CProtein interaction78%MGAT2Protein interaction77%
Tissue Expression6 tissues
Heart
100%
Bone Marrow
58%
Brain
28%
Lung
17%
Ovary
16%
Liver
8%
Gene Interaction Network
Click a node to explore
MGAT5MGAT3MGAT5BMGAT4DLGALS3MGAT4CMGAT2
PROTEIN STRUCTURE
Preparing viewer…
PDB6YJS · 1.60 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.41Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.30 [0.22–0.41]
RankingsWhere MGAT5 stands among ~20K protein-coding genes
  • #4,893of 20,598
    Most Researched98 · top quartile
  • #2,167of 17,882
    Most Constrained (LOEUF)0.41 · top quartile
Genes detectedMGAT5
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Reprogramming CD8+ T-cell Branched N-Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing.
PMID: 40828448
Cancer Immunol Res · 2025
1.00
2
Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies.
PMID: 35044789
Sci Transl Med · 2022
0.90
3
In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma.
PMID: 31548728
Nat Biotechnol · 2019
0.80
4
Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression.
PMID: 36689079
Cell Oncol (Dordr) · 2023
0.70
5
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance.
PMID: 38912584
JCI Insight · 2024
0.60